SecBot SecBot
PRESS-RELEASE ·Filed Mar 2, 2026

ZYME

Zymeworks Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Traders should monitor the sBLA submission for Ziihera in first-line GEA in 1Q 2026 and potential NCCN guideline inclusion as near-term catalysts. The Royalty Pharma financing de-risks the balance sheet and extends cash runway beyond 2028, supporting continued buybacks or strategic acquisitions. Upcoming data presentations at AACR in April 2026 could provide additional R&D momentum.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$23.31
T+0 close · Mar 2, 2026 · via day close
Latest settled
+8.97%
T+60 · $25.40
Vs SPY
−0.36%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $23.31entry
  2. T+1 · 9mo ago +4.89%α +5.81% · $24.45
  3. T+5 · 8mo ago +4.03%α +5.24% · $24.25
  4. T+20 · 8mo ago +3.86%α +11.80% · $24.21
  5. T+60 · 6mo ago +8.97%α −0.36% · $25.40
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zymeworks reported strong 2025 financial results with 39% revenue growth to $106.0 million and a 34% reduction in net loss to $81.1 million. The company secured $250.0 million in non-dilutive financing from Royalty Pharma and is executing a $125.0 million share repurchase program, having already used $62.5 million. Key catalysts include the potential U.S. approval and 2026 launch of Ziihera in first-line HER2+ gastroesophageal cancer, which could trigger up to $440.0 million in milestone payments.

Key Financial Metrics

Revenue
$106.0M
+39.0% YoY
EPS
$-1.08
Deal Value
$250.0M

Key Facts

  • Total revenue for 2025 was $106.0 million, up 39% from $76.3 million in 2024
  • Net loss for 2025 was $81.1 million, a 34% improvement from $122.7 million in 2024
  • Entered into $250.0 million non-recourse royalty-backed note financing with Royalty Pharma
  • Utilized $62.5 million of a $125.0 million share repurchase program as of March 2, 2026
  • Partner Jazz expects to submit sBLA for Ziihera in first-line HER2+ GEA in 1Q 2026 with potential U.S. launch in 2H 2026
  • Eligible for up to $440.0 million in milestone payments from Jazz and BeOne for Ziihera approvals in GEA across U.S., Europe, Japan, and China
  • Cash, cash equivalents, and marketable securities totaled $270.6 million as of December 31, 2025
  • Guided for approximately $300.0 million in adjusted gross operating expenses (non-GAAP) over 2026–2028, with 2026 expenses ~20% lower than 2025

Financial Impact

Revenue increased by $29.7 million YoY; net loss reduced by $41.6 million; $250.0 million non-dilutive financing secured; $62.5 million returned to shareholders via buybacks

revenuenet losscash runwaydilutionshare count

Risk Factors

  • Regulatory delay or rejection of Ziihera sBLA in first-line GEA
  • Failure to realize anticipated milestone payments from partners
  • Clinical setbacks in wholly-owned pipeline programs (ZW191, ZW251, ZW209, ZW1528)
  • Execution risk around cost discipline and operating expense reductions

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3247159

Track record

25 reports on ZYME

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
  2. Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $26.24 Now $26.24 −0.00% settles Dec 14
  4. Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
  5. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
  6. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
  7. Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
  8. Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
  9. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
  10. Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (12h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026